Structure-Guided Discovery of Potent, Selective, and Orally Bioavailable Werner Syndrome RecQ Helicase Inhibitors for the Treatment of Microsatellite Instability-High Tumors
Journal of Medicinal Chemistry · 25.06.2026 · 69 (12) · 14492-14512
DOI: 10.1021/acs.jmedchem.6c00331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 03.06.2026. Verfasst von Qibang Sui und 12 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai2…. Hauptthemen laut MEDLINE: Werner Syndrome Helicase, Antineoplastic Agents, Microsatellite Instability, Enzyme Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: China Association for Science and Technology, National Key Research and Development Program of China, Youth Innovation Promotion Association of the Chinese Academy of Sciences.
Abstract (Originalsprache)
Despite recent advances in immunotherapy for microsatellite instability-high (MSI-H) tumors, challenges of resistance persist, necessitating alternative therapeutic approaches. The synthetic lethal interaction between WRN helicase inhibition and MSI status presents a promising therapeutic strategy. Guided by the key structural features of the WRN-HRO761 complex, we rationally designed two classes of WRN inhibitors─spirocyclic compounds and benzo-fused heterocyclic analogs─by targeting the solvent-exposed region. Among these, Q15 exhibited potent in vitro activity and excellent cellular selectivity. Compared with HRO761 in vivo, Q15 demonstrated more favorable oral pharmacokinetic properties and superior antitumor efficacy at 10 mg/kg, comparable efficacy at 20 mg/kg, and achieved complete tumor regression at 40 mg/kg. Preliminary safety evaluation further indicated that Q15 possesses a favorable safety profile. These findings support Q15 as a promising WRN inhibitor candidate for the treatment of MSI-H tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai201203, China.
- Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong266003, China.
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing210023, China.
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou310024, China.
- University of Chinese Academy of Sciences, Beijing100049, China.
- School of Life Science and Technology, ShanghaiTech University, Shanghai201210, China.
ORCID-Profile: Qibang Sui, Dan Teng, Chong Qin, Sulin Zhang, Mingyue Zheng
Förderung
- China Association for Science and Technology
- National Key Research and Development Program of China
- Youth Innovation Promotion Association of the Chinese Academy of Sciences
- National Natural Science Foundation of China
- Chinese Academy of Sciences
Zitieren
APA
Sui, Q., Wang, D., Hou, H., Shi, C., Cai, X., Zhou, Y., Cui, R., Li, M., Liu, J., Teng, D., Qin, C., Zhang, S., & Zheng, M. (2026). Structure-Guided Discovery of Potent, Selective, and Orally Bioavailable Werner Syndrome RecQ Helicase Inhibitors for the Treatment of Microsatellite Instability-High Tumors. Journal of Medicinal Chemistry, 69(12), 14492-14512. https://doi.org/10.1021/acs.jmedchem.6c00331
Vancouver
Sui Q, Wang D, Hou H, Shi C, Cai X, Zhou Y, et al. Structure-Guided Discovery of Potent, Selective, and Orally Bioavailable Werner Syndrome RecQ Helicase Inhibitors for the Treatment of Microsatellite Instability-High Tumors. Journal of Medicinal Chemistry. 2026;69(12):14492-14512. doi:10.1021/acs.jmedchem.6c00331
BibTeX
@article{Sui2026,
author = {Sui, Qibang and Wang, Dan and Hou, Hui and Shi, Chen and Cai, Xiaoying and Zhou, Yuanyang and Cui, Rongrong and Li, Manjia and Liu, Jia and Teng, Dan and Qin, Chong and Zhang, Sulin and Zheng, Mingyue},
title = {Structure-Guided Discovery of Potent, Selective, and Orally Bioavailable Werner Syndrome RecQ Helicase Inhibitors for the Treatment of Microsatellite Instability-High Tumors},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {12},
pages = {14492--14512},
doi = {10.1021/acs.jmedchem.6c00331}
}
EUVIMED